Quick Answer
Esperion Therapeutics, Inc. reported Total Revenue of $403.13 million for fiscal year 2025.
Esperion Therapeutics, Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2025 | $403.13M | +21.3% |
| 2024 | $332.31M | +185.7% |
| 2023 | $116.33M | +54.1% |
| 2022 | $75.47M | -3.8% |
| 2021 | $78.45M | -65.5% |
| 2020 | $227.55M | +53.4% |
| 2019 | $148.36M | — |
| 2018 | $0.00 | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $87.31M | +69.1% | +6.0% |
| June 30, 2025 | $82.39M | +11.6% | +26.8% |
| March 31, 2025 | $65.00M | -52.8% | +25.9% |
| September 30, 2024 | $51.63M | +52.0% | -30.1% |
| June 30, 2024 | $73.83M | +186.3% | -46.4% |
| March 31, 2024 | $137.74M | +466.1% | +305.5% |
| September 30, 2023 | $33.97M | +79.0% | +31.7% |
| June 30, 2023 | $25.79M | +36.9% | +6.0% |
- Esperion Therapeutics, Inc. showed an increase of +21.3% in Total Revenue compared to the prior fiscal year.
- The most recent figure is from Esperion Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: